Natco Pharma approves up to INR 1,300 crore rights issue and demerger changes

Corporate Actions View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹825.00

prior close

₹821.55

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.5%+0.6% vs market

Pharmaceuticals peers, median of 174sector-0.2%+0.3% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Smallcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.2

15m

+0.2

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1-0.5+0.6-0.2+0.3

Next day

-0.8-0.5-0.2-0.7-0.0

-1.0-1.0-0.0-0.7-0.3

-1.1-3.4+2.3-2.2+1.1

-1.2-3.6+2.4-2.5+1.3

-0.7-2.8+2.1-2.3+1.6

-1.0-1.3+0.3-0.8-0.2

15d

-0.7-5.1+4.3-2.3+1.6

-4.2-5.1+0.9-5.1+0.8

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On September 9, 2026, the board approved a rights issue of fully paid equity shares of face value INR 2 each, raising no more than INR 1,300 crore from eligible shareholders. The issue price, entitlement ratio, number of shares, use of funds and record date are not yet set. After completion, Natco will amend its crop health demerger scheme while maintaining the existing share swap ratio.

Likely market impact

Shareholders may need to contribute cash, while others may see ownership shrink. Price, entitlement ratio and use of funds are not yet known.